



# Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis

Peter Willeit<sup>1,2\*</sup>, Julia Raschenberger<sup>3,9</sup>, Emma E. Heydon<sup>2</sup>, Sotirios Tsimikas<sup>4</sup>, Margot Haun<sup>3</sup>, Agnes Mayr<sup>5</sup>, Siegfried Weger<sup>6</sup>, Joseph L. Witztum<sup>4</sup>, Adam S. Butterworth<sup>2</sup>, Johann Willeit<sup>1</sup>, Florian Kronenberg<sup>3</sup>, Stefan Kiechl<sup>1\*</sup>

**1** Department of Neurology, Innsbruck Medical University, Innsbruck, Austria, **2** Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, **3** Division of Genetic Epidemiology, Innsbruck Medical University, Innsbruck, Austria, **4** Department of Medicine, University of California San Diego, La Jolla, United States of America, **5** Department of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy, **6** Department of Internal Medicine, Bruneck Hospital, Bruneck, Italy

## Abstract

**Background:** Short telomeres have been linked to various age-related diseases. We aimed to assess the association of telomere length with incident type 2 diabetes mellitus (T2DM) in prospective cohort studies.

**Methods:** Leucocyte relative telomere length (RTL) was measured using quantitative polymerase chain reaction in 684 participants of the prospective population-based Bruneck Study (1995 baseline), with repeat RTL measurements performed in 2005 (n = 558) and 2010 (n = 479). Hazard ratios for T2DM were calculated across quartiles of baseline RTL using Cox regression models adjusted for age, sex, body-mass index, smoking, socio-economic status, physical activity, alcohol consumption, high-density lipoprotein cholesterol, log high-sensitivity C-reactive protein, and waist-hip ratio. Separate analyses corrected hazard ratios for within-person variability using multivariate regression calibration of repeated measurements. To contextualise findings, we systematically sought PubMed, Web of Science and EMBASE for relevant articles and pooled results using random-effects meta-analysis.

**Results:** Over 15 years of follow-up, 44 out of 606 participants free of diabetes at baseline developed incident T2DM. The adjusted hazard ratio for T2DM comparing the bottom vs. the top quartile of baseline RTL (i.e. shortest vs. longest) was 2.00 (95% confidence interval: 0.90 to 4.49; P = 0.091), and 2.31 comparing the bottom quartile vs. the remainder (1.21 to 4.41; P = 0.011). The corresponding hazard ratios corrected for within-person RTL variability were 3.22 (1.27 to 8.14; P = 0.014) and 2.86 (1.45 to 5.65; P = 0.003). In a random-effects meta-analysis of three prospective cohort studies involving 6,991 participants and 2,011 incident T2DM events, the pooled relative risk was 1.31 (1.07 to 1.60; P = 0.010; I<sup>2</sup> = 69%).

**Conclusions/Interpretation:** Low RTL is independently associated with the risk of incident T2DM. To avoid regression dilution biases in observed associations of RTL with disease risk, future studies should implement methods correcting for within-person variability in RTL. The causal role of short telomeres in T2DM development remains to be determined.

**Citation:** Willeit P, Raschenberger J, Heydon EE, Tsimikas S, Haun M, et al. (2014) Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis. PLoS ONE 9(11): e112483. doi:10.1371/journal.pone.0112483

**Editor:** Arthur J. Lustig, Tulane University Health Sciences Center, United States of America

**Received:** June 30, 2014; **Accepted:** October 6, 2014; **Published:** November 12, 2014

**Copyright:** © 2014 Willeit et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. Anonymised data are available on request to the corresponding author for researchers who meet the criteria for access to confidential data, including accreditation as approved researcher by the local data sharing committee and signing of a data sharing agreement with the study. The values underlying Figures 1, 3, and 5 are included in the Supporting Information files and enables reproduction of the figures (including the meta-analysis).

**Funding:** This project was funded by a grant of the 'Tiroler Wissenschaftsfonds', Austria. The Bruneck Study was supported by the 'Pustertaler Verein zur Prävention von Herz- und Hirngefäesserkrankungen, Gesundheitsbezirk Bruneck' and the 'Assessorat für Gesundheit', Province of Bolzano, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* Email: pwilleit@outlook.com (PW); stefan.kiechl@i-med.ac.at (SK)


<sup>9</sup> These authors contributed equally to this work.

## Introduction

Telomeres are the extreme ends of eukaryotic chromosomes, stabilising and protecting the chromosome from degradation [1,2]. Telomeres shorten with each cellular division, accelerated by inflammation and oxidative stress, and, below a critical length, the apoptotic programme of the cell is induced [1,3].

Short telomeres are associated with increased risk of several age-related diseases [2] such as cardiovascular diseases [4–8] and cancer [9–11]. It has been suggested that biological ageing reflected by telomere length is also related to the development of type 2 diabetes (T2DM) [12]. Proposed pathophysiological mechanisms include a reduction in beta-cell mass [13], impaired insulin secretion [14] and adipocyte insulin resistance elicited by






**Figure 1. Baseline characteristics of the Bruneck Study population and their cross-sectional association with leucocyte relative telomere length (1995, n = 684).** Standardised mean differences in leucocyte relative telomere length were adjusted for age and sex. Asterisks indicate level of statistical significance: \*P≤0.05; \*\*P≤0.01; \*\*\*P≤0.001. The mean (SD) of HbA1c was 5.8% (3.7%) in DCCT-derived units and 40 mmol/mol (17 mmol/mol) in SI units. Abbreviations: ApoB, apolipoprotein B; ApoB-IC, apoB-immune complexes; CI, confidence interval; Cu-OxLDL, copper-oxidised low-density lipoprotein; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; IgG, immunoglobulin G; IgM, immunoglobulin M; LDL, low-density lipoprotein; RTL, relative telomere length; MDA, malondialdehyde; OxPL/apoB, oxidised phospholipids on apolipoprotein B-100; SD, standard deviation; RLU, relative light unit; SMD, standardised mean difference; WHR, waist-hip ratio.  
doi:10.1371/journal.pone.0112483.g001

survey area are referred to the same hospital and the network existing between hospital and practitioners allows retrieval of full medical information. There were no cases of type 1 diabetes mellitus in this cohort.

**Literature-based meta-analysis**

Prospective studies of the association of telomere length with the risk of incident T2DM were sought using the databases PubMed, Web of Science and EMBASE. The search strategy combined



**Figure 2. Distribution of baseline leucocyte relative telomere length in the Bruneck Study according to different disease states (1995, n=684).** Abbreviations: RTL, relative telomere length; T2DM, type 2 diabetes mellitus. There were 390 participants with normoglycaemia, 216 participants with impaired fasting glucose, and 78 participants with a clinical diagnosis of T2DM. doi:10.1371/journal.pone.0112483.g002

keywords related to the exposure of interest (“telomere” or “telomeres”), the outcome (“diabetes”) and the study design (“cohort” or “prospective” or “longitudinal” or “hazard” or “risk” or “odds”). We included articles published before March 26<sup>th</sup> 2014 and applied no language restrictions. We scanned the reference lists of identified studies and reviews for any additional relevant articles. Because of their vulnerability to reverse causation biases, retrospective case-control studies were excluded from the meta-analysis (whereas nested case-control studies conducted within prospective cohort studies were included). Study level characteristics and participant characteristics were extracted using a standardised data extraction form, including information on: geographic location, population source, year of baseline survey, number of participants, mean age and age range, percentage of males, telomere length assay method, number of incident T2DM cases, duration of follow-up, and reported measures of association (i.e. hazard ratios, odds ratios, or other measures of relative risk) with corresponding confidence intervals and degree of adjustment for confounders. If studies had reported measures of association for different degree of adjustment, the most adjusted estimate was used in the meta-analysis. We assessed the quality of the included studies with the Newcastle-Ottawa scale, a quality score ranging from zero to nine points [38].


**Statistical analysis**

The statistical analysis was conducted according to a pre-specified analysis plan. Continuous variables were summarised as means (standard deviations) or medians (interquartile ranges), and dichotomous variables as numbers (percentages). Cross-sectional associations between RTL and other participant characteristics were determined using unadjusted and age- and sex-adjusted linear regression. To quantify within-person variability of RTL, regression dilution ratios were calculated using information from all available RTL measurements in 1995, 2005 and 2010 [39].

**Table 1. Association of leucocyte relative telomere length with incident type 2 diabetes mellitus in the Bruneck Study (n = 606, 44 events).**

Exposure/adjustment	Quartile 1	Quartile 2	Quartile 3	Quartile 4	Quartile 4 vs. remainder
	(Longest RTL)			(Shortest RTL)	
<b>Baseline RTL</b>					
Median (range) of RTL, T/S ratios	1.35 (1.21–3.87)	1.13 (1.05–1.21)	0.98 (0.92–1.05)	0.82 (0.52–0.91)	
Incidence rate of T2DM per 1,000 person-years	5.2 (2.9, 9.4)	3.1 (1.4, 6.9)	5.4 (3.0, 9.8)	10.6 (6.5, 17.2)	
Hazard ratio for T2DM (95% CI)					
Adjusted for age and sex	1.00 [Reference]	0.58 (0.22, 1.58)	0.95 (0.41, 2.22)	1.89 (0.85, 4.18)	2.21 (1.17, 4.16)*
Plus BMI, smoking, SES, and physical activity	1.00 [Reference]	0.57 (0.21, 1.56)	0.96 (0.41, 2.24)	1.89 (0.85, 4.21)	2.22 (1.17, 4.21)*
Plus alcohol consumption, HDL-C, log hsCRP, and WHR	1.00 [Reference]	0.58 (0.21, 1.58)	0.99 (0.42, 2.32)	2.00 (0.90, 4.49)	2.31 (1.21, 4.41)*
<b>Long-term average RTL</b>					
Median (range) of RTL, T/S ratios	1.29 (1.18–2.94)	1.12 (1.06–1.18)	1.02 (0.97–1.06)	0.89 (0.63–0.96)	
Incidence rate of T2DM per 1,000 person-years	3.6 (1.8, 7.3)	5.0 (2.7, 9.4)	4.5 (2.3, 8.6)	12.2 (7.6, 19.6)	
Hazard ratio for T2DM (95% CI)					
Adjusted for age and sex	1.00 [Reference]	1.36 (0.53, 3.45)	1.16 (0.44, 3.05)	3.24 (1.29, 8.15)*	2.76 (1.41, 5.41)**
Plus BMI, smoking, SES, and physical activity	1.00 [Reference]	1.24 (0.48, 3.20)	1.10 (0.41, 2.92)	3.05 (1.21, 7.70)*	2.73 (1.39, 5.36)**
Plus alcohol consumption, HDL-C, log hsCRP, and WHR	1.00 [Reference]	1.25 (0.49, 3.23)	1.11 (0.42, 2.94)	3.22 (1.27, 8.14)*	2.86 (1.45, 5.65)**

Asterisks indicate level of statistical significance: \*P≤0.05; \*\*P≤0.01; \*\*\*P≤0.001. Abbreviations: BMI, body mass index; HDL-C, high density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; RTL, relative telomere length; SES, socio-economic status; T2DM, type 2 diabetes mellitus; WHR, waist-hip ratio. Participants with a baseline history of type 2 diabetes mellitus were excluded from the analysis (n = 78). doi:10.1371/journal.pone.0112483.t001



**Figure 3. Association of leucocyte relative telomere length on a risk of type 2 diabetes mellitus in the Bruneck Study (n = 606, 44 events over follow-up 1995–2010).** Cox models were adjusted for age, sex, body mass index, smoking, socio-economic status, physical activity, alcohol consumption, high density lipoprotein cholesterol, log high-sensitivity C-reactive protein, and waist-hip ratio. Abbreviations: CI, confidence interval; HR, hazard ratio; RTL, relative telomere length; T2DM, type 2 diabetes mellitus. doi:10.1371/journal.pone.0112483.g003

Regression dilution ratios can range from 0 to 1, with 1 indicating absence of within-person variability. Long-term average RTL was estimated by multivariate linear-mixed regression calibration model that allowed for a random intercept at the participant level [40].

The time-to-event analysis excluded participants with baseline T2DM. Person-years of follow-up were accrued from the baseline in 1995 until diagnosis of T2DM, death or October 1, 2010, whichever came first. Cox proportional hazard models were used to assess the association between RTL and T2DM incidence. Following a previous report of a possible threshold effect in associations of RTL with T2DM risk [41], we categorised study participants into groups of RTL quartiles and compared T2DM risk across these groups. The analyses were progressively adjusted for age, sex, body mass index, smoking, socio-economic status, physical activity, alcohol consumption, high-density lipoprotein cholesterol, log high-sensitivity C-reactive protein, and waist-hip ratio. The proportional hazards assumption was tested and confirmed using Schoenfeld residuals. To assess effect modification by sex, subsidiary analyses used interaction term between sex and RTL quartiles and tested for interaction with a likelihood ratio test. For the literature-based meta-analysis, we did not need to rescale published relative risks (RRs), because all eligible studies reported RRs on the same scale, i.e. for a comparison of extreme RTL quartiles. Hazard ratios (HRs) and odds ratios were assumed to approximate the same measure of RR. Reported RRs were pooled using random-effects meta-analysis. Heterogeneity between studies was quantified using the  $I^2$  statistic and tested by a standard  $\chi^2$  test [42]. Potential publication and small-study bias was

formally assessed using Egger's test [43]. All analyses were conducted with Stata 12.0. A two-sided P value  $\leq 0.05$  was considered statistically significant. The presentation of results follows the recommendations by the STROBE and PRISMA guidelines (see **Checklists S1** and **S2**).

## Results

### Baseline characteristics


The median RTL at baseline was 1.05 T/S ratios (interquartile range: 0.92–1.21). **Figure 1** summarises baseline characteristics of the study population (n = 684). The mean age of study participants was 63 years (SD, 11) and 49% were men. The multivariable adjusted regression dilution ratio of RTL was 0.68 (95% confidence interval: 0.61 to 0.76). We investigated the age- and sex-adjusted cross-sectional association at baseline between several characteristics and standardised RTL (**Figure 1**). The strongest association was observed with age. On average, every one standard deviation older age (11 years) was associated with 0.22 shorter standardised RTL ( $-0.30$  to  $-0.15$ ;  $P = 2 \times 10^{-9}$ ). There was no significant correlation of RTL with other parameters, including markers of inflammation, oxidative stress and hyperglycaemia (all  $P > 0.05$ ).

We further investigated whether baseline RTL differed according to baseline T2DM status (**Figure 2**). We observed no significant difference in RTL across the groups of normoglycaemic participants (n = 390), participants with impaired fasting glucose levels (n = 216), and participants with a clinical diagnosis of T2DM (n = 78) ( $P_{\text{trend}} = 0.346$ ).

### Association of leucocyte telomere length with risk of incident type 2 diabetes mellitus

The Cox regression analyses excluded 78 participants with a baseline diagnosis of T2DM. Between 1995 and 2010, 44 of the 606 individuals in the study population developed T2DM (incidence rate, 5.8 per 1,000 person years [4.3 to 7.8]). **Table 1** compares T2DM risk across quartiles of decreasing RTL. In a comparison of the bottom vs. top quartile of baseline RTL, the age- and sex-adjusted HR was 1.89 (0.85 to 4.18;  $P = 0.116$ ). The most adjusted model yielded a HR of 2.00 (0.90 to 4.49;  $P = 0.091$ ). In a comparison of the bottom quartile of baseline RTL vs. the remainder, the respective HRs were 2.21 (1.17 to 4.16;  $P = 0.015$ ) and 2.31 (1.21 to 4.41;  $P = 0.011$ ). **Table 1** also shows analyses using long-term average RTL. In the most adjusted model, participants in the bottom quartile of long-term average RTL had a HR of 3.22 (1.27, to 8.14;  $P = 0.014$ ) compared with the top RTL quartile and 2.86 (1.45 to 5.65;  $P = 0.002$ ) compared with all other quartiles. We observed that increases in T2DM risk were confined to the bottom RTL quartile (particularly when using long-term average RTL), in line with a possible threshold effect (**Figure 3**). Results were similar in analyses that excluded the first five years of follow-up (data not shown). There was no evidence for differential associations in women and men (likelihood-ratio tests for interaction:  $P = 0.776$  for baseline RTL;  $P = 0.571$  for long-term average RTL).

Subsidiary analysis evaluated the association of a baseline diagnosis of T2DM with RTL change over 15 years. There was no significant difference in RTL dynamics according to baseline T2DM status (mean standardised RTL change in participants with vs. without T2DM at baseline [95% confidence interval]:  $-0.068$  [ $-0.450$  to  $0.314$ ];  $P = 0.727$ ). This analysis had limited power because it included only 400 study participants with RTL measurements available both in 1995 and 2010, of which only 20 had T2DM at baseline.



**Figure 4. Study flow diagram of the literature-based meta-analysis.** The figure is based on the 2009 PRISMA flow diagram template (available from <http://www.prisma-statement.org/statement.htm>).

doi:10.1371/journal.pone.0112483.g004

### Literature-based meta-analysis

Our literature search retrieved 429 records (**Figure 4**). We excluded 170 duplicate records and 240 records on the basis of their title and abstract. We carefully checked the full-text of the remaining 19 records and excluded a further 17 articles, including 12 case-control studies and 1 study that selectively recruited participants with impaired glucose tolerance [44]. Finally, together with the Bruneck Study, we identified three relevant prospective studies eligible for inclusion in the literature-based meta-analysis [41,45].

The characteristics of the three studies are summarised in **Figure 5**. The Strong Heart Family Study is a multigenerational study of American Indian families in four states of the USA, which recorded 292 incident T2DM events over a mean of 5.5 years (defined according to the 1997 American Diabetes Association criteria) [41]. The observational arm of the Women's Health


Initiative used a nested case-control analysis that included 1,675 incident cases of T2DM (defined based on self-report or T2DM hospitalisation) [45]. Overall, information from the three studies was available on 6,991 participants and 2,011 incident T2DM events recorded over a weighted mean of 6.6 years. Baseline age of participants ranged from 14 to 93 years; 18% were male. The reported multivariable adjusted RRs for T2DM were quantitatively similar in the Bruneck Study and the Strong Heart Family Study (**Figure 5**). The pooled RR for all three studies was 1.31 (1.07 to 1.60;  $P = 0.010$ ) for a comparison of the bottom vs. the top quartile of baseline RTL. Between-study heterogeneity was moderate with an  $I^2$  of 69% (0% to 91%) (**Figure 5**). There was no evidence of publication bias ( $P = 0.460$ ). We could not calculate a pooled RR corrected for long-term variability, because such an estimate was only available for the Bruneck Study.

### Discussion

In the present report, we demonstrate a significant positive association between shorter leucocyte telomeres and T2DM risk. In the Bruneck Study, the increase in risk appeared to be confined to the bottom quartile of RTL (i.e. participants with the shortest RTL) and was particularly evident in analyses correcting for long-term variability in RTL. In a pooled analysis of published reports from three prospective cohort studies, we estimated that people in the bottom RTL quartile had a 31% (7 to 60%) higher risk of developing T2DM than those in the longest RTL quartile.

RTL is a dynamic measure that may decrease but also increase over time [18–27]. Possible sources of variability in measured RTL include the (i) cumulative effect of environmental and behavioural exposures, (ii) varying telomerase activity, (iii) stress-induced repopulation of peripheral blood by recently dividing hematopoietic bone marrow cells, (iv) shifts in the cellular composition of peripheral blood leucocytes (differential blood count) and release of leucocyte subpopulations during acute infections [46,47] (i.e. “true variation”), and (v) measurement error. Previous epidemiological studies on RTL and T2DM risk have not been able to correct for RTL variability, potentially yielding biased estimates. The Bruneck study, which made such a correction on the basis of up to three repeated measurements taken over a follow-up time of 15 years, indicates an independent association of shorter telomeres with T2DM, of greater magnitude than previously reported. The within-person variability of RTL was comparable to that of commonly measured cardio-metabolic risk markers, such as blood pressure or high-sensitivity C-reactive protein. It was lower than previously reported [19] because we further optimised our technique for RTL quantification, including consistent DNA extraction method and re-measurement in quadruplicate.

Previous studies have suggested a possible threshold effect of associations of RTL with age-related diseases, including T2DM [41]. Our study independently confirms this hypothesis, demonstrating an elevation in T2DM risk only in the quartile of participants with the shortest telomeres. As suggested by Zhao *et al.* [41], one intriguing biological explanation for this finding could be the crossing of the “Hayflick limit” [3], beyond which cells cease to divide and undergo apoptosis. Furthermore, several pieces of evidence support that short telomeres play an important role in T2DM pathogenesis, rather than being an epiphenomenon of a pre-diabetic metabolic state. In mice, deletion of the telomerase RNA component (TERC) lowers the replication capacity of beta-cells and thereby leads to a reduced islet mass and failure to produce adequate amounts of insulin in response to glucose stimulation and high fat diet [13]. It has also been proposed that short telomeres impede insulin secretion through inhibition of



**Figure 5. Description and meta-analysis of published data from three prospective cohort studies on the association of short telomeres and risk of type 2 diabetes mellitus.** Published relative risks were pooled by random-effects meta-analysis. In the Bruneck Study and the Strong Heart Family Study, type 2 diabetes was defined according to the 1997 American Diabetes Association criteria. In the WHI Observational Study, diabetes was defined based on self-report and hospitalisation for type 2 diabetes. All three studies measured telomere length with a quantitative polymerase chain reaction technique. \*Reported relative risks were additionally adjusted for two variables in the Bruneck Study (HDL cholesterol and log hsCRP), three variables in the Strong Heart Family Study (age<sup>2</sup>, fasting glucose, total triglycerides), and three variables in the Women’s Health Initiative Observational Study (date of blood collection, clinical centre, hormone therapy). †Max. ‡Mean. §The Women’s Health Initiative Observational Study involved postmenopausal women who proved to be ineligible or unwilling to be randomised as part of the Women’s Health Initiative Clinical Trial. Abbreviations: CI, confidence interval; NOS, Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta-analyses; T2DM, type 2 diabetes mellitus; WHI, Women’s Health Initiative. doi:10.1371/journal.pone.0112483.g005

calcium-mediated exocytosis [14]. In adipocytes, cellular senescence leads to insulin resistance, which is reversible by inhibition of p53 activity [15]. In a study of 22,715 women and 1,445 incident T2DM events, Zee *et al.* have shown that genetic variants related to telomere pathways are associated with T2DM risk [48]. On the other hand, evidence suggests that diabetes has a marked impact on telomere length dynamics. High levels of oxidative stress observed in diabetes patients [16] accelerate telomere attrition because the high guanine content of telomeres makes them particularly vulnerable to reactive oxygen species [17]. Xu *et al.* demonstrated that new-borns have significantly shorter telomeres if their mother suffered from gestational diabetes [49]. However, the Nurses’ Health Study has quantified genetic predisposition to T2DM with a risk score combining 36 genetic variants and ruled out a strong causal impact of T2DM on telomere dynamics (although the study was powered to only detect effects of ≥9% explained variability) [50].

To place our findings in context of the currently available epidemiological literature, we performed a systematic literature review and meta-analysis of the available published evidence from prospective cohort studies on the topic. The pooled RR for a comparison of bottom vs. top quartiles of telomere length (i.e. shortest vs. longest) involving data from 6,991 participants and 2,011 incident T2DM cases was 1.31 (1.07 to 1.60). In contrast to an earlier meta-analysis [12], we excluded articles reporting on case-control studies, thereby limiting the effect of reverse causation biases in our analysis. However, because the present evaluation

was based on observational studies, we cannot fully exclude the possibility that our estimates are confounded by other factors or the consequence of the often extended lag time between manifestation and diagnosis of T2DM.

Our study has several strengths. First, the Bruneck Study is representative of the general population (with a recruitment process using municipal registers and with a response rate >90%). It therefore crucially expands our knowledge from select populations (i.e. populations from specific ethnic backgrounds or other non-representative samples) to the healthy general community. Second, the Bruneck cohort is extremely well-characterised with 100% follow-up over 15 years and high-quality ascertainment of both clinical endpoints and potential confounders. The detailed characterisation of the study participants helped us estimate independent associations adjusted for a large panel of proposed risk markers for T2DM, including adiposity measures, smoking, social class, and physical activity. Third, the present study had a prospective design and used rigorous baseline examinations to exclude all individuals with T2DM at baseline, thereby minimising any reverse causation biases. Supplementary analyses that excluded the first five years of follow-up yielded qualitatively similar results. Fourth, to enhance validity of the measurement, we extracted all available DNA samples with the same DNA extraction kit. Although samples taken in 1995 and 2005 had been previously analysed [5,10], samples from all three time points were reanalysed simultaneously to avoid a measurement error over the time period. In addition, a bias according to the ascertainment

of RTL on different qPCR plates was avoided by positioning the available DNA samples from a single individual from different time points side by side on the same plate. To maximise accuracy, RTL measurements were performed in quadruplicate, in an intensively standardised and automated manner, and within a short period of time by personnel blinded to the characteristics and outcome of the study participants. We have demonstrated previously that RTL measurement using qPCR, as performed in the Bruneck Study, is highly correlated with measurement of absolute telomere length using a Southern Blot technique ( $r=0.765$ ) [5]. Fifth, we were able to model long-term average RTL and provide effect estimates for T2DM corrected for fluctuations in RTL over time. Finally, we performed a comprehensive literature review and combined data from previously published prospective studies.

Our study also has potential limitations. First, the Bruneck Study population was entirely Caucasian and therefore findings are only generalizable to this ethnicity. Previous investigations by the Nurses' Health Study on differences by ethnicity (Caucasian, African Americans, Hispanic, and Asian) have shown generally comparable associations of RTL with T2DM incidence [45]. Second, telomere length was measured in circulating blood leucocytes only. More precise assessments and comparisons of telomere length in different tissues (e.g. liver, muscle, adipose tissue, and pancreas) would be helpful to better understand the role of telomeres in disease development but, clearly, this is not feasible in large population studies. Third, the number of incident T2DM events was low in the Bruneck Study limiting our ability to conduct more detailed investigations (e.g. extensive subgroup analyses), although major findings were independently confirmed in the literature-based meta-analysis. Fourth, the meta-analyses of published data used single baseline measurements of RTL to study the association with subsequent T2DM. Our analysis of RTL

reproducibility over up to 15 years suggests that previous studies could have substantially underestimated potential associations with T2DM. Finally, because the present evidence is limited to observational studies in primarily adult populations, no judgement on the causal involvement of telomere length in T2DM can be made on the basis of the present report.

## Conclusion

Low RTL is independently associated with the risk of incident T2DM. To avoid regression dilution bias in observed associations of RTL with disease risk, future studies should implement methods correcting for within-person variability in RTL. Whether there is a causal involvement of telomeres in T2DM development remains to be determined.

## Supporting Information

### Checklist S1 STROBE Statement—Checklist of items that should be included in reports of cohort studies.

(PDF)

### Checklist S2 PRISMA 2009 Checklist.

(PDF)

### File S1 Underlying data for Figure 1, 3 and 5.

(XLSX)

## Author Contributions

Conceived and designed the experiments: PW AM SW JW FK SK. Performed the experiments: JR ST MH JLW FK. Analyzed the data: PW. Wrote the paper: PW JR EEH ST MH AM SW JLW ASB JW FK SK. Collected data on baseline characteristics and disease incidence of the Bruneck Study participants: PW AM SW JW SK.

## References

- Blackburn EH (1991) Structure and function of telomeres. *Nature* 350: 569–573.
- Calado RT, Young NS (2009) Telomere diseases. *N Engl J Med* 361: 2353–2365.
- Hayflick L (1965) The limited in vitro lifetime of human diploid cell strains. *Exp Cell Res* 37: 614–636.
- Weischer M, Bojesen SE, Cawthon RM, Freiberg JJ, Tybjaerg-Hansen A, et al. (2012) Short telomere length, myocardial infarction, ischemic heart disease, and early death. *Arterioscler Thromb Vasc Biol* 32: 822–829.
- Willeit P, Willeit J, Brandstätter A, Ehrlénbach S, Mayr A, et al. (2010) Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. *Arterioscler Thromb Vasc Biol* 30: 1649–1656.
- Zee RY, Michaud SE, Germer S, Ridker PM (2009) Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. *Clin Chim Acta* 403: 139–141.
- Brouillette SW, Moore JS, McMahon AD, Thompson JR, Ford I, et al. (2007) Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. *Lancet* 369: 107–114.
- Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, et al. (2014) Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ* 349: g4227.
- Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA (2011) The association of telomere length and cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 20: 1238–1250.
- Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, et al. (2010) Telomere length and risk of incident cancer and cancer mortality. *JAMA* 304: 69–75.
- Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, et al. (2011) Shortened telomere length is associated with increased risk of cancer: a meta-analysis. *PLoS One* 6: e20466.
- Zhao J, Miao K, Wang H, Ding H, Wang DW (2013) Association between telomere length and type 2 diabetes mellitus: a meta-analysis. *PLoS One* 8: e79993.
- Kuhlow D, Florian S, von Figura G, Weimer S, Schulz N, et al. (2010) Telomerase deficiency impairs glucose metabolism and insulin secretion. *Aging (Albany NY)* 2: 650–658.
- Guo N, Parry EM, Li LS, Kembou F, Lauder N, et al. (2011) Short telomeres compromise  $\beta$ -cell signaling and survival. *PLoS One* 6: e17858.
- Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, et al. (2009) A crucial role for adipose tissue p53 in the regulation of insulin resistance. *Nat Med* 15: 1082–1087.
- Roberts CK, Sindhu KK (2009) Oxidative stress and metabolic syndrome. *Life Sci* 84: 705–712.
- Houben JM, Moonen HJ, van Schooten FJ, Hageman GJ (2008) Telomere length assessment: biomarker of chronic oxidative stress? *Free Radic Biol Med* 44: 235–246.
- Weischer M, Bojesen SE, Nordestgaard BG (2014) Telomere shortening unrelated to smoking, body weight, physical activity, and alcohol intake: 4,576 general population individuals with repeat measurements 10 years apart. *PLoS Genet* 10: e1004191.
- Willeit P, Willeit J, Kloss-Brandstätter A, Kronenberg F, Kiechl S (2011) Fifteen-year follow-up of association between telomere length and incident cancer and cancer mortality. *JAMA* 306: 42–44.
- Svenson U, Nordfjäll K, Baird D, Roger L, Osterman P, et al. (2011) Blood cell telomere length is a dynamic feature. *PLoS One* 6: e21485.
- Huzen J, Wong LS, van Veldhuisen DJ, Samani NJ, Zwinderman AH, et al. (2014) Telomere length loss due to smoking and metabolic traits. *J Intern Med* 275: 155–163.
- Rehkopf DH, Dow WH, Rosero-Bixby L, Lin J, Epel ES, et al. (2014) Seasonal variation of peripheral blood leukocyte telomere length in Costa Rica: A population-based observational study. *Am J Hum Biol* 26: 367–375.
- Epel ES, Merkin SS, Cawthon R, Blackburn EH, Adler NE, et al. (2009) The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. *Aging (Albany NY)* 1: 81–88.
- Nordfjäll K, Svenson U, Norrback KF, Adolfsen R, Lenner P, et al. (2009) The individual blood cell telomere attrition rate is telomere length dependent. *PLoS Genet* 5: e1000375.
- Aviv A, Chen W, Gardner JP, Kimura M, Brimacombe M, et al. (2009) Leukocyte telomere dynamics: longitudinal findings among young adults in the Bogalusa Heart Study. *Am J Epidemiol* 169: 323–329.
- Chen W, Kimura M, Kim S, Cao X, Srinivasan SR, et al. (2011) Longitudinal versus cross-sectional evaluations of leukocyte telomere length dynamics: age-dependent telomere shortening is the rule. *J Gerontol A Biol Sci Med Sci* 66: 312–319.

27. Farzaneh-Far R, Lin J, Epel E, Lapham K, Blackburn E, et al. (2010) Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study. *PLoS One* 5: e8612.
28. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, et al. (2002) Toll-like receptor 4 polymorphisms and atherogenesis. *N Engl J Med* 347: 185–192.
29. Kloss-Brandstätter A, Willeit P, Lamina C, Kiechl S, Kronenberg F (2010) Correlation between baseline telomere length and shortening over time—spurious or true? *Int J Epidemiol* 40: 840–841.
30. Baecke JA, Burema J, Frijters JE (1982) A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr* 36: 936–942.
31. Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, et al. (2012) Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. *J Am Coll Cardiol* 60: 2218–2229.
32. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, et al. (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. *Diabetes Care* 23: 57–63.
33. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18: 499–502.
34. Cawthon RM (2002) Telomere measurement by quantitative PCR. *Nucleic Acids Res* 30: e47.
35. Raschenberger J, Kollerits B, Hammerer-Lercher A, Rantner B, Stadler M, et al. (2013) The association of relative telomere length with symptomatic peripheral arterial disease: results from the CAVASIC study. *Atherosclerosis* 229: 469–474.
36. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 29: e45.
37. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, et al. (2003) Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26: 3160–3167.
38. Wells G, Shea B, Peterson J, Welch V, Losos M, et al. (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.htm](http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm). Accessed 12 May 2014.
39. Wood AM, White I, Thompson SG, Lewington S, Danesh J (2006) Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. *Int J Epidemiol* 35: 1570–1578.
40. Fibrinogen Studies Collaboration (2009) Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. *Stat Med* 28: 1067–1092.
41. Zhao J, Zhu Y, Lin J, Matsuguchi T, Blackburn E, et al. (2014) Short leukocyte telomere length predicts risk of diabetes in american indians: the strong heart family study. *Diabetes* 63: 354–362.
42. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *BMJ* 327: 557–560.
43. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315: 629–634.
44. Hovatta I, de Mello VD, Kananen L, Lindström J, Eriksson JG, et al. (2012) Leukocyte telomere length in the Finnish Diabetes Prevention Study. *PLoS One* 7: e34948.
45. You NC, Chen BH, Song Y, Lu X, Chen Y, et al. (2012) A prospective study of leukocyte telomere length and risk of type 2 diabetes in postmenopausal women. *Diabetes* 61: 2998–3004.
46. Cohen S, Janicki-Deverts D, Turner RB, Casselbrant ML, Li-Korotky HS, et al. (2013) Association between telomere length and experimentally induced upper respiratory viral infection in healthy adults. *JAMA* 309: 699–705.
47. Lin J, Epel E, Cheon J, Kroenke C, Sinclair E, et al. (2010) Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. *J Immunol Methods* 352: 71–80.
48. Zee RY, Ridker PM, Chasman DI (2011) Genetic variants of 11 telomere-pathway gene loci and the risk of incident type 2 diabetes mellitus: the Women's Genome Health Study. *Atherosclerosis* 218: 144–146.
49. Xu J, Ye J, Wu Y, Zhang H, Luo Q, et al. (2014) Reduced fetal telomere length in gestational diabetes. *PLoS One* 9: e86161.
50. Du M, Prescott J, Cornelis MC, Hankinson SE, Giovannucci E, et al. (2013) Genetic predisposition to higher body mass index or type 2 diabetes and leukocyte telomere length in the Nurses' Health Study. *PLoS One* 8: e52240.